Group 1 - Spyre Therapeutics Inc. (NASDAQ:SYRE) has been recognized as one of the 10 Best Debt Free Small Cap Stocks to Buy Now, indicating significant upside potential for investors [1] - The company has enrolled its first patient in the Phase 2 SKYWAY trial, which targets multiple autoimmune diseases and assesses its lead antibody program in patients unresponsive to standard treatments [2] - As this is Spyre's second Phase 2 program, initial data is expected in 2026, with several proof-of-concept readouts planned over the next two years [3] Group 2 - Spyre Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory bowel disease and is noted for being one of the Best Debt Free Stocks [3]